Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.72 |
| ▸ | GART | P22102 | 6/20 | 0.70 |
| ▸ | FPGS | Q05932 | 2/20 | 0.64 |
| ▸ | DHFR | P00374 | 3/20 | 0.59 |
| ▸ | ATIC | P31939 | 4/20 | 0.55 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.54 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704421 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL258465 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL8061 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL8060 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL29616598 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL3199681 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL5829838 | 0.96 | SOST (0.66) | SOSTGARTFPGSDHFRATIC | |
| Tetrahydrofolate SCHEMBL18703989 | 0.94 | SOST (0.82) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL11475679 | 0.93 | SOST (0.62) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL8160135 | 0.93 | SOST (0.71) | SOSTGARTFPGSDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633809-A1 | GAS EXCHANGE DURING ELECTROWETTING OPERATIONS | Nuclera Ltd (GB) | 2025-10-22 | — | — | EP | claimed |
| US-20240316050-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-09-26 | — | — | US | claimed |
| WO-2024127038-A1 | GAS EXCHANGE DURING ELECTROWETTING OPERATIONS | NUCLERA LTD (GB) | 2024-06-20 | — | — | WO | claimed |
| EP-4262806-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | Oxford University Innovation Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| CN-116723842-A | Treatment of conditions associated with low BH4 bioavailability | 牛津大学科技创新有限公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2022136851-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-06-30 | — | — | WO | claimed |
| EP-2773355-B1 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN | SOUTH ALABAMA MEDICAL SCIENCE FOUND (US) | 2022-06-08 | — | — | EP | claimed |
| EP-4722228-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | The University of Tokyo (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4665861-A1 | USE OF TANDEM FACIAL AMPHIPHILES FOR PROTEIN EXPRESSION | Nuclera Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | AGAIN BIO APS (DK) | 2025-11-27 | — | — | US | disclosed |
| EP-4633809-A1 | GAS EXCHANGE DURING ELECTROWETTING OPERATIONS | Nuclera Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250297244-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SEVERE COVID 19 AND OTHER INFLAMMATORY AUTOIMMUNE DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4615970-A1 | MICRO-COMPARTMENTALIZED ULTRA-HIGH THROUGHPUT SCREENING FROM SINGLE COPY GENE LIBRARIES | Paris Sciences et Lettres (FR) | 2025-09-17 | — | — | EP | disclosed |
| EP-2773355-B1 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN | SOUTH ALABAMA MEDICAL SCIENCE FOUND (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220160712-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS AND FOR PREDICTING THE RESPONSE TO METHOTREXATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
| EP-2401696-B1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | INTREXON CEU INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-7674490-B2 | Food and vitamin preparations containing the natural isomer of reduced folates | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674490-B2 | Food and vitamin preparations containing the natural isomer of reduced folates | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070207136-A1 | Food and vitamin preparations containing the natural isomer of reduced folates | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION | 2007-09-06 | — | — | US | disclosed |
| US-20070207136-A1 | Food and vitamin preparations containing the natural isomer of reduced folates | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | HSD17B10, HSD17B12, HADHB | SOST 4848/4885GART 923/4885FPGS 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.